Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cote GM"" wg kryterium: Autor


Tytuł :
Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue Tumors.
Autorzy :
Chebib I; James Homer Wright Pathology Laboratories Department of Internal Medicine, Division of Hematology/Oncology Departments of Orthopedic Oncology Surgical Oncology Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Taylor MS
Nardi V
Rivera MN
Lennerz JK
Cote GM
Choy E
Lozano Calderón SA
Raskin KA
Schwab JH
Mullen JT
Chen YE
Hung YP
Nielsen GP
Deshpande V
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2021 Jun 10. Date of Electronic Publication: 2021 Jun 10.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial.
Autorzy :
Mellinghoff IK; Neurology, Memorial Sloan Kettering Cancer Center .
Penas-Prado M; Neuro-Oncology, The University of Texas MD Anderson Cancer Center.
Peters KB; Duke Medical Center.
Burris HA; Sarah Cannon Research Institute.
Maher EA; -Center for Neuro-Oncology, The University of Texas Southwestern Medical Center.
Janku F; The University of Texas MD Anderson Cancer Center.
Cote GM; Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School.
de la Fuente MI; Neurology, University of Miami/Sylvester Comprehensive Cancer Center.
Clarke JL; Neurological Surgery, University of California, San Francisco.
Ellingson BM; Radiological Sciences, David Geffen School of Medicine at UCLA.
Chun S; Neurology, University of California, Los Angeles.
Young RJ; Radiology, Memorial Sloan Kettering Cancer Center.
Liu H; Agios Pharmaceuticals (United States).
Choe S; Agios Pharmaceuticals, Inc.
Lu M; Agios Pharmaceuticals (United States).
Le K; Agios Pharmaceuticals (United States).
Hassan I; Clinical Development, The University of Texas MD Anderson Cancer Center.
Steelman L; Agios Pharmaceuticals (United States).
Pandya SS; Agios Pharmaceuticals, Inc.
Cloughesy TF; David Geffen School of Medicine, Department of Neurology, University of California, Los Angeles.
Wen PY; Center For Neuro-Oncology, Dana-Farber Cancer Institute.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 02. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Autorzy :
Jerby-Arnon L; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Neftel C; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Shore ME; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Weisman HR; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Mathewson ND; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Immunology, Harvard Medical School, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
McBride MJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Haas B; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Izar B; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Columbia Center for Translational Immunology, New York, NY, USA.; Columbia University Medical Center, Division of Hematology and Oncology, New York, NY, USA.
Volorio A; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Boulay G; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Cironi L; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Richman AR; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Broye LC; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Gurski JM; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Luo CC; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Mylvaganam R; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nguyen L; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Mei S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Melms JC; Columbia Center for Translational Immunology, New York, NY, USA.; Columbia University Medical Center, Division of Hematology and Oncology, New York, NY, USA.
Georgescu C; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Cohen O; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Buendia-Buendia JE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Segerstolpe A; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Sud M; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Cuoco MS; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Bioinformatics and Systems Biology Graduate Program, University of California, San Diego, La Jolla, CA, USA.
Labes D; Flow Cytometry Facility, Department of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Gritsch S; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Zollinger DR; NanoString Technologies, Seattle, WA, USA.
Ortogero N; NanoString Technologies, Seattle, WA, USA.
Beechem JM; NanoString Technologies, Seattle, WA, USA.
Petur Nielsen G; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Chebib I; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Nguyen-Ngoc T; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Montemurro M; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Cote GM; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
Choy E; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
Letovanec I; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Cherix S; Department of Orthopedics, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Wagle N; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Sorger PK; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Haynes AB; Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Mullen JT; Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Stamenkovic I; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Rivera MN; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kadoch C; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Wucherpfennig KW; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Immunology, Harvard Medical School, Boston, MA, USA.
Rozenblatt-Rosen O; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Genentech, South San Francisco, CA, USA.
Suvà ML; Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. .
Riggi N; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. .; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. .
Regev A; Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA, USA. .; Genentech, South San Francisco, CA, USA. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2021 Feb; Vol. 27 (2), pp. 289-300. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*
Carcinogenesis/*genetics
Oncogene Proteins, Fusion/*genetics
Sarcoma, Synovial/*drug therapy
Cell Line, Tumor ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Histone Deacetylase Inhibitors/therapeutic use ; Histone Deacetylases/genetics ; Histone Deacetylases/therapeutic use ; Humans ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogenes/genetics ; RNA-Seq ; Sarcoma, Synovial/genetics ; Sarcoma, Synovial/pathology ; Single-Cell Analysis
Czasopismo naukowe
Tytuł :
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Autorzy :
Berezhnoy A; MacroGenics, Rockville, MD, USA.
Sumrow BJ; MacroGenics, Rockville, MD, USA.
Stahl K; MacroGenics, Rockville, MD, USA.
Shah K; MacroGenics, Rockville, MD, USA.
Liu D; MacroGenics, Rockville, MD, USA.
Li J; MacroGenics, Brisbane, CA, USA.
Hao SS; MacroGenics, Rockville, MD, USA.
De Costa A; MacroGenics, Brisbane, CA, USA.
Kaul S; Bio-ClinPharm Consulting, Cranbury, NJ, USA.
Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Cote GM; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Luke JJ; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Sanborn RE; Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, OR, USA.
Sharma MR; START-Midwest, Grand Rapids, MI, USA.
Chen F; MacroGenics, Brisbane, CA, USA.
Li H; MacroGenics, Rockville, MD, USA.
Diedrich G; MacroGenics, Rockville, MD, USA.
Bonvini E; MacroGenics, Rockville, MD, USA.
Moore PA; MacroGenics, Rockville, MD, USA.
Pokaż więcej
Źródło :
Cell reports. Medicine [Cell Rep Med] 2020 Dec 22; Vol. 1 (9), pp. 100163. Date of Electronic Publication: 2020 Dec 22 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Autorzy :
Gounder M; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: .
Schöffski P; Department of General Medical Oncology, and Laboratory of Experimental Oncology, University Hospitals Leuven, KU Leuven, Leuven Cancer Institute, Leuven, Belgium.
Jones RL; Royal Marsden Hospital and Institute of Cancer Research, London, UK.
Agulnik M; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Cote GM; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Villalobos VM; Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA; Janssen Pharmaceuticals, Spring House, PA, USA.
Attia S; Mayo Clinic, Jacksonville, FL, USA.
Chugh R; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Chen TW; National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Jahan T; University of California San Francisco, San Francisco, CA, USA.
Loggers ET; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gupta A; The Hospital for Sick Children and Princess Margaret Cancer Center, Toronto, ON, Canada.
Italiano A; Institut Bergonie and University of Bordeaux, Bordeaux, France.
Demetri GD; Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA.
Ratan R; MD Anderson Cancer Center, Houston, TX, USA.
Davis LE; Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
Mir O; Gustave Roussy Cancer Institute, Paris, France.
Dileo P; University College London Hospitals NHS Foundation Trust, London, UK.
Van Tine BA; School of Medicine, Washington University in St Louis, St Louis, MO, USA.
Pressey JG; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Lingaraj T; Epizyme, Cambridge, MA, USA.
Rajarethinam A; Epizyme, Cambridge, MA, USA.
Sierra L; Epizyme, Cambridge, MA, USA; Bristol Myers Squibb, Cambridge, MA, USA.
Agarwal S; Epizyme, Cambridge, MA, USA.
Stacchiotti S; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. 1423-1432. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Benzamides/*administration & dosage
Pyridones/*administration & dosage
SMARCB1 Protein/*genetics
Sarcoma/*drug therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzamides/adverse effects ; Benzamides/pharmacokinetics ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/pharmacokinetics ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Progression-Free Survival ; Pyridones/adverse effects ; Pyridones/pharmacokinetics ; Sarcoma/genetics ; Sarcoma/pathology ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma.
Autorzy :
Mellinghoff IK; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
Ellingson BM; UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Touat M; Drug Development Department, Gustave Roussy Cancer Center, Villejuif, France.
Maher E; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX.
De La Fuente MI; Department of Neurology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Holdhoff M; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Cote GM; Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA.
Burris H; Sarah Cannon Research Institute, Nashville, TN.
Janku F; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Young RJ; Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Huang R; Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA.
Jiang L; Biostatistics, Agios Pharmaceuticals, Cambridge, MA.
Choe S; Bioinformatics, Agios Pharmaceuticals, Cambridge, MA.
Fan B; Pharmacology, Agios Pharmaceuticals, Cambridge, MA.
Yen K; Clinical Sciences, Agios Pharmaceuticals, Cambridge, MA.
Lu M; Clinical Sciences, Agios Pharmaceuticals, Cambridge, MA.
Bowden C; Medical, Agios Pharmaceuticals, Cambridge, MA.
Steelman L; Medical, Agios Pharmaceuticals, Cambridge, MA.
Pandya SS; Medical, Agios Pharmaceuticals, Cambridge, MA.
Cloughesy TF; Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, Los Angeles, CA.
Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Oct 10; Vol. 38 (29), pp. 3398-3406. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain Neoplasms/*drug therapy
Glioma/*drug therapy
Glycine/*analogs & derivatives
Isocitrate Dehydrogenase/*genetics
Pyridines/*administration & dosage
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Brain Neoplasms/enzymology ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/adverse effects ; Female ; Glioma/enzymology ; Glioma/genetics ; Glioma/pathology ; Glycine/administration & dosage ; Glycine/adverse effects ; Humans ; Isocitrate Dehydrogenase/antagonists & inhibitors ; Male ; Middle Aged ; Mutation ; Pyridines/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma.
Autorzy :
Li X; Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.
Dean DC; Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Cote GM; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Zou L; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hornicek FJ; Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Yu S; Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Duan Z; Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, 615 Charles E. Young Dr. S., Los Angeles, CA 90095, USA.
Pokaż więcej
Źródło :
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2020 Sep 14; Vol. 12, pp. 1758835920956900. Date of Electronic Publication: 2020 Sep 14 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.
Autorzy :
Hung YP; Departments of Pathology.
Diaz-Perez JA; Department of Pathology and Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL.
Cote GM; Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital Cancer Center, Boston, MA.
Wejde J; Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
Schwab JH; Orthopedics.
Nardi V; Departments of Pathology.
Chebib IA; Departments of Pathology.
Deshpande V; Departments of Pathology.
Selig MK; Departments of Pathology.
Bredella MA; Radiology, Massachusetts General Hospital and Harvard Medical School.
Rosenberg AE; Department of Pathology and Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL.
Nielsen GP; Departments of Pathology.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2020 Sep; Vol. 44 (9), pp. 1213-1223.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*/analysis
Biomarkers, Tumor*/genetics
Cell Dedifferentiation*
Chordoma/*classification
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Boston ; Chordoma/chemistry ; Chordoma/genetics ; Chordoma/secondary ; Female ; Florida ; Genetic Predisposition to Disease ; High-Throughput Nucleotide Sequencing ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Mutation ; Neoplasm Grading ; Phenotype ; SMARCB1 Protein/analysis ; SMARCB1 Protein/genetics ; Treatment Outcome ; Tumor Suppressor Protein p53/genetics ; Young Adult
Czasopismo naukowe
Tytuł :
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Autorzy :
Tap WD; Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY.
Villalobos VM; University of Colorado Anschutz Medical Campus, Aurora, CO.
Cote GM; Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital Cancer Center, Boston, MA.
Burris H; Sarah Cannon Research Institute, Nashville, TN.
Janku F; Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Mir O; Department of Ambulatory Care, Gustave Roussy Cancer Campus, Villejuif, France.
Beeram M; START Center for Cancer Care, San Antonio, TX.
Wagner AJ; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jiang L; Agios Pharmaceuticals, Cambridge, MA.
Wu B; Agios Pharmaceuticals, Cambridge, MA.
Choe S; Agios Pharmaceuticals, Cambridge, MA.
Yen K; Agios Pharmaceuticals, Cambridge, MA.
Gliser C; Agios Pharmaceuticals, Cambridge, MA.
Fan B; Agios Pharmaceuticals, Cambridge, MA.
Agresta S; Agios Pharmaceuticals, Cambridge, MA.
Pandya SS; Agios Pharmaceuticals, Cambridge, MA.
Trent JC; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 May 20; Vol. 38 (15), pp. 1693-1701. Date of Electronic Publication: 2020 Mar 24.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Chondrosarcoma/*drug therapy
Enzyme Inhibitors/*therapeutic use
Glycine/*analogs & derivatives
Pyridines/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Enzyme Inhibitors/pharmacology ; Female ; Glycine/pharmacology ; Glycine/therapeutic use ; Humans ; Male ; Middle Aged ; Pyridines/pharmacology
Czasopismo naukowe
Tytuł :
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma.
Autorzy :
Keskin T
Bakaric A
Waszyk P
Boulay G
Torsello M
Cornaz-Buros S
Chevalier N
Geiser T
Martin P
Volorio A
Iyer S
Kulkarni A
Letovanec I
Cherix S
Cote GM
Choy E
Digklia A
Montemurro M
Chebib I
Nielsen PG
Carcaboso AM
Mora J
Renella R
Suvà ML
Fusco C
Provero P
Rivera MN
Riggi N
Stamenkovic I
Pokaż więcej
Źródło :
Cell reports [Cell Rep] 2020 Apr 14; Vol. 31 (2), pp. 107539.
Typ publikacji :
Published Erratum
Tytuł :
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.
Autorzy :
Lietz CE; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Garbutt C; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.; Illumina, Inc., San Diego, United States.
Barry WT; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Deshpande V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Chen YL; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Lozano-Calderon SA; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Wang Y; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, United States.
Lawney B; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, United States.
Ebb D; Pediatric Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Cote GM; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Duan Z; Department of Orthopaedic Surgery, UCLA, Los Angeles, CA, United States.
Hornicek FJ; Department of Orthopaedic Surgery, UCLA, Los Angeles, CA, United States.
Choy E; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Petur Nielsen G; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Haibe-Kains B; Department of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Quackenbush J; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, United States.
Spentzos D; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Mar 10; Vol. 10 (1), pp. 4409. Date of Electronic Publication: 2020 Mar 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Regulatory Networks*
Bone Neoplasms/*pathology
MicroRNAs/*genetics
Osteosarcoma/*pathology
Sequence Analysis, RNA/*methods
Adolescent ; Adult ; Aged ; Biomarkers, Tumor/genetics ; Biopsy ; Bone Neoplasms/genetics ; Child ; Child, Preschool ; Cohort Studies ; Female ; Humans ; Machine Learning ; Male ; Middle Aged ; Osteosarcoma/genetics ; Phenotype ; Prognosis ; RNA, Messenger/genetics ; Survival Analysis ; Young Adult
Czasopismo naukowe
Tytuł :
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Autorzy :
Cote GM; Division of Hematology and Oncology, Department of Medicine, Boston, MA, USA. Electronic address: .
Choy E; Division of Hematology and Oncology, Department of Medicine, Boston, MA, USA.
Chen T; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Marino-Enriquez A; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Morgan J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Merriam P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thornton K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wagner AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nathenson MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Demetri G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
George S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Feb; Vol. 126, pp. 21-32. Date of Electronic Publication: 2019 Dec 31.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carbolines/*therapeutic use
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Sarcoma/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carbolines/administration & dosage ; Carbolines/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Humans ; Kaplan-Meier Estimate ; Leukopenia/chemically induced ; Male ; Middle Aged ; Neoplasm Metastasis ; Neutropenia/chemically induced ; Research Design ; Sarcoma/classification ; Sarcoma/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies